Alfacalcidol 0.25 Capsules
Each soft gelatin capsule contains Alfacalcidol (1a hydroxyvitamin D 3 ) 0.25 (green capsule)
Each soft gelatin capsule contains 1.25 gms of calcium carbonate from an organic source (oyster shell) equivalent to Elemental calcium 500 , Alfacalcidol BP 0.25 mcg
Alfacalcidol is prescribed for treating conditions in which calcium metabolism is disturbed due to impaired 1-a hydroxylation, such as reduced renal function; in other disorders associated with Vitamin D resistance; and in calcium malabsorption of osteoporosis.
The main indications are:
- Hypoparathyroidism (with bone disease);
- Hypophosphataemic vitamin d-resistant rickets and osteomalacia;
- Nutritional and malabsorptive rickets and osteomalacia;
- Pseudo-deficiency (d-dependent type i) rickets with osteomalacia;
- Renal bone disease (renal osteodystrophy);
The dosage and administration of Alfacalcidol should be adjusted according to
the indication-specific notes as follows.
The initial dose is All indications, excepting osteoporosis:
Children 20 kg and over
Excepting in renal osteodystrophy 1 /day
In renal osteodystrophy
0.04 – 0.08 /kg/day
Children under 20 kg
The dose should subsequently be adjusted to avoid hypercalcaemia, according to the biochemical response.
Plasma calcium levels (preferably corrected for protein binding) should initially be measured weekly.
The dose of Alfacalcidol can be increased by increments of 0.25 to 0.5 /day.
Most adults respond to doses of 1 to 3 /day.
Once the dose is stabilised, calcium levels should be measured periodically.
Children with renal osteodystrophy seem to need relatively higher doses than adults and may even need the adult dose.
1 capsule twice a day or as recommended by your physician
Alfacalcidol should not be administered in the presence of hypercalcaemia, hyperphosphataemia (except when occurring with hypoparathyroidism) or hypermagnesaemia.
Alfacalcidol is contraindicated in patients with evidence of Vitamin D toxicity or known hypersensitivity to the effects of Vitamin D or any of its analogues.
Alfacalcidol plus should not be administered in the presence of hypercalcaemia, hyperphos-phataemia (except when occurring with hypoparathyroidism) or hypermagnesaemia.
Alfacalcidol plus is contraindicated in patients with evidence of Vitamin D toxicity or known hypersensitivity to the effects of Vitamin D or any of its analogues.
- Blister strip of 10 capsules;